San Francisco, United States
GraphWear Technologies Inc., a promising venture in the Health Care and Medical Devices industry, is captivating attention with its innovative approach to chronic disease management. Headquartered in the United States and founded in 2015, the company embraces the tagline #notblood, highlighting its commitment to non-invasive diagnostic solutions.
GraphWear's flagship product, a needle-free continuous glucose monitoring system, is currently undergoing clinical trials for diabetes management. This breakthrough technology positions the company as a unique player aiming to enhance patient quality of life without relying on traditional testing methods like blood and urine samples.
In their latest financial milestone, GraphWear secured a substantial $20.50M in a Series B investment round on 01 October 2021. Esteemed investors, including Builders VC, Mayfield, Mission BioCapital, and VSC Ventures, endorse GraphWear's vision. This significant capital intake empowers the company to potentially redefine chronic disease diagnostics and monitoring on a global scale.
